Advancing combination drug development through quantitative medicine
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: ROMERO, Klaus (Critical Path Institute, Clinical Pharmacology and Quantitative Medicine, Tucson, United States)
- Co-author(s): Klaus Romero: Clinical Pharmacology and Quantitative Medicine, Critical Path Institute, Tucson, United States
Debra Hanna: Critical Path to TB Drug Regimens (CPTR) Initiative, Critical Path Institute, Tucson, United States
The development of novel tuberculosis (TB) multi-drug regimens that are more efficacious and of shorter duration requires a robust drug development pipeline. Advances in quantitative modeling and simulation can be used to maximize the utility of patient-level data from prior and contemporary clinical trials, thus optimizing study design for.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.